Has the warning been removed already?

The FDA requested removal from application holders; implementing a labelling change is a process rather than an instant event, and other jurisdictions make their own decisions. The action to date is the request and the review supporting it.

Why did this take two and a half years?

Because assembling participant-level data across 91 trials from multiple development programmes is a substantial undertaking, and because removing a warning requires more evidence than declining to add one. The delay reflects the evidentiary standard rather than inaction.

Does this change anything for someone taking one of these medicines?

It changes what the label says, not what any individual should do. Decisions about a prescription belong with the prescribing clinician. Nothing supplied on this site is a version of or an alternative to any of these medicines.

Research & Regulatory News

A Warning Comes Off Three GLP-1 Labels

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-243 cited sources

The FDA has requested that manufacturers remove all language about suicidal ideation and behaviour from the labelling of Saxenda, Wegovy and Zepbound. It follows a meta-analysis of 91 placebo-controlled clinical trials covering 107,910 participants, which found no increased risk of those outcomes.

Key facts

Date: 13 January 2026
Action: Request to remove warning language from labelling
Products named: Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide)
Trials in the analysis: 91, placebo-controlled
Total participants: 107,910
GLP-1-treated: 60,338
Placebo: 47,572
Outcomes assessed: Suicidal behaviour and ideation, anxiety, depression, irritability, psychosis
Investigation opened: July 2023

What was announced

The FDA issued a Drug Safety Communication on 13 January 2026 requesting that application holders remove information regarding the risk of suicidal ideation and behaviour from the labelling of GLP-1 receptor agonist medications. The named products are Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide). The basis given is a meta-analysis of 91 placebo-controlled clinical trials drawn from across GLP-1 receptor agonist development programmes, comprising 107,910 participants of whom 60,338 received a GLP-1 receptor agonist and 47,572 received placebo. The analysis found no increased risk of suicidal ideation or behaviour, nor of related psychiatric adverse events including anxiety, depression, irritability and psychosis.

How the question arose

The FDA opened a formal investigation in July 2023 following postmarketing reports of suicidal ideation and behaviour in patients using these medications. Postmarketing reports are the earliest and least reliable form of safety information - voluntary, unverified, without a denominator of exposed people - and their function is to prompt investigation rather than to establish anything. That is what happened here. A preliminary Drug Safety Communication in January 2024 reported no clear evidence of causation while noting that the small number of cases in individual trials left the risk estimate uncertain.

What Europe did, and when

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee reached its conclusion on 12 April 2024, considerably earlier. Having reviewed non-clinical studies, clinical trials, post-marketing surveillance data and additional studies including one based on electronic health records that the agency conducted itself, the PRAC concluded that the available evidence does not support a causal association between the GLP-1 receptor agonists dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide and suicidal and self-injurious thoughts and actions. Its stated consequence was that no update to the product information was warranted. The UK's MHRA reached a similar conclusion. It is worth being precise that the European decision was not to change the labelling, which is a different act from the FDA's later decision to remove text from it.

Why the trial-level evidence was decisive

The recurring problem in this question is confounding. People prescribed weight-management medicines have, as a group, higher baseline rates of depression and related conditions than the general population - partly because obesity and depression co-occur, partly because the decision to seek treatment is itself associated with distress. Any observational comparison inherits that. A published meta-analysis of observational studies illustrates the consequence: pooling four studies gave a risk ratio of 0.568 with a 95% confidence interval from 0.077 to 4.205 and heterogeneity of 98% - an estimate compatible with almost any conclusion. Randomised allocation across 91 trials removes the confounding by construction and supplies the event numbers that individual trials lacked.

What this does not establish

That the risk is zero. A large randomised analysis constrains how large an effect could have escaped detection; it does not prove absence, and no study design does. It also does not extend beyond the populations enrolled, the durations studied or the products analysed. Commentary accompanying these reviews has continued to recommend monitoring of mental health in people with existing psychiatric conditions, which remains a matter for prescribing clinicians rather than for labelling.

Why this belongs in a peptide reference library

Because it is a complete, dated, publicly documented example of a safety signal being opened, investigated across two regulatory systems and formally closed - which is rare. Most signals persist unresolved. It is also a demonstration of the gulf between what exists for licensed medicines and what exists for research material: three products here have a 107,910-participant randomised safety database and labelling that regulators actively revise. Compounds supplied for laboratory research have none of that, and no article on this site should ever be read as suggesting otherwise.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Has the warning been removed already?: The FDA requested removal from application holders; implementing a labelling change is a process rather than an instant event, and other jurisdictions make their own decisions. The action to date is the request and the review supporting it.
Does this apply to all GLP-1 drugs?: The FDA communication names Saxenda, Wegovy and Zepbound. The EMA's earlier review covered dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Neither statement covers every compound in the class, and investigational agents have no labelling to change.
Why did this take two and a half years?: Because assembling participant-level data across 91 trials from multiple development programmes is a substantial undertaking, and because removing a warning requires more evidence than declining to add one. The delay reflects the evidentiary standard rather than inaction.
Does this change anything for someone taking one of these medicines?: It changes what the label says, not what any individual should do. Decisions about a prescription belong with the prescribing clinician. Nothing supplied on this site is a version of or an alternative to any of these medicines.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum